An Oncolinea Pharmaceuticals Inc. patent describes nucleosides acting as DNA repair inhibitors and thus reported to be useful for the treatment of cancer.

A team at the University of Geneva has developed prodrugs of antimicrobial agents and particularly conjugates comprising antimicrobial agents covalently bound to a tocopheryl or tocotrienyl group through a linker with micelle formation ability and improved stability.

Work at Nankai University has led to the development of heparin trisaccharides potentially useful for the treatment of sepsis.

Sanofi SA has prepared and tested pyrazolopyrazinone compounds acting as cystine/glutamate transporter (solute carrier family 7 member 11; SLC7A11; xCT) inhibitors.

Complement factor B (CFB) inhibitors are described in a Novartis AG patent and reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy and eye disorders, among others.

An Abbvie Inc. patent has disclosed thiazolo [5,4-b] pyridine compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL).

Rarified Biosciences Inc. has reported mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, graft-vs.-host disease, systemic lupus erythematosus, scleroderma, psoriatic arthritis, primary sclerosing cholangitis, rheumatoid arthritis and inflammatory bowel disease.

Research at Design Therapeutics Inc. has led to the discovery of conjugates consisting of a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence linked to a protein binding moiety through oligomeric backbone linker. They are transcription modulators reported to be useful for the treatment of Huntington’s disease.

Voronoi and Voronoi Bio Inc. have patented serine/threonine-protein kinase B-raf (BRAF), Raf kinase and Raf kinase B (V600E mutant) inhibitors reported to be useful for the treatment of cancer.

Sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers have been reported in a Humanwell Healthcare (Group) Co. Ltd. patent as potentially useful for the treatment of pain.